| Sierra Rose Family Physicians Medical Group | |
|
8735 Sierra College Blvd Suite 100 Roseville CA 95661-5920 | |
| (916) 786-5908 | |
| Not Available |
| Full Name | Sierra Rose Family Physicians Medical Group |
|---|---|
| Speciality | Family Medicine |
| Location | 8735 Sierra College Blvd, Roseville, California |
| Authorized Official Name and Position | Suzie Allison (MANAGER) |
| Authorized Official Contact | 9167970333 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Sierra Rose Family Physicians Medical Group 576 N Sunrise Ave Ste 220 Roseville CA 95661-2847 Ph: (916) 786-5908 | Sierra Rose Family Physicians Medical Group 8735 Sierra College Blvd Suite 100 Roseville CA 95661-5920 Ph: (916) 786-5908 |
| NPI Number | 1215012141 |
|---|---|
| Provider Enumeration Date | 10/26/2006 |
| Last Update Date | 03/11/2022 |
| Medicare PECOS PAC ID | 1951474774 |
|---|---|
| Medicare Enrollment ID | O20080725000701 |
News Archive
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
D-Pharm Ltd., announced today that the Korean Food & Drug Administration (KFDA) approved the Investigational New Drug application for the Phase III MACSI study of DP-b99 in Korea. The IND has been submitted by D-Pharm's co-development partner in South Korea, Yungjin Pharmaceutical Company Ltd..
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in the October 9 issue of JAMA.
A recent environmental study from the United Kingdom, currently available on the bioRxiv preprint server, shows that certain common surfaces could represent an infectious risk if contaminated with high concentrations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – albeit the level of viable viral particles is likely to be low.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215012141 | NPI | - | NPPES |
| CS7519 | Other | GA | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (California) | Primary |
| Provider Name | Linda M Agresti |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1255402723 PECOS PAC ID: 2961439492 Enrollment ID: I20050726000780 |
News Archive
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
D-Pharm Ltd., announced today that the Korean Food & Drug Administration (KFDA) approved the Investigational New Drug application for the Phase III MACSI study of DP-b99 in Korea. The IND has been submitted by D-Pharm's co-development partner in South Korea, Yungjin Pharmaceutical Company Ltd..
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in the October 9 issue of JAMA.
A recent environmental study from the United Kingdom, currently available on the bioRxiv preprint server, shows that certain common surfaces could represent an infectious risk if contaminated with high concentrations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – albeit the level of viable viral particles is likely to be low.
› Verified 9 days ago
| Provider Name | Ernestina T Agresti |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1558432021 PECOS PAC ID: 6406884410 Enrollment ID: I20050801000600 |
News Archive
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
D-Pharm Ltd., announced today that the Korean Food & Drug Administration (KFDA) approved the Investigational New Drug application for the Phase III MACSI study of DP-b99 in Korea. The IND has been submitted by D-Pharm's co-development partner in South Korea, Yungjin Pharmaceutical Company Ltd..
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in the October 9 issue of JAMA.
A recent environmental study from the United Kingdom, currently available on the bioRxiv preprint server, shows that certain common surfaces could represent an infectious risk if contaminated with high concentrations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – albeit the level of viable viral particles is likely to be low.
› Verified 9 days ago
News Archive
Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.
D-Pharm Ltd., announced today that the Korean Food & Drug Administration (KFDA) approved the Investigational New Drug application for the Phase III MACSI study of DP-b99 in Korea. The IND has been submitted by D-Pharm's co-development partner in South Korea, Yungjin Pharmaceutical Company Ltd..
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in the October 9 issue of JAMA.
A recent environmental study from the United Kingdom, currently available on the bioRxiv preprint server, shows that certain common surfaces could represent an infectious risk if contaminated with high concentrations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – albeit the level of viable viral particles is likely to be low.
› Verified 9 days ago
Richard B. D. Chun, M.d. Professional Corporation Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 729 Sunrise Ave, Ste 619, Roseville, CA 95661 Phone: 916-783-7118 | |
Capitol Gastroenterology Consultants Medical Group, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4 Medical Plaza Dr Ste 205, Roseville, CA 95661 Phone: 916-773-6200 Fax: 916-782-4550 | |
Veeone Medical Group Ii Professional Corporation Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1420 Rocky Ridge Dr Ste 300, Roseville, CA 95661 Phone: 850-459-6238 | |
Wellspace Health Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 151 N Sunrise Ave Ste 1309, Roseville, CA 95661 Phone: 916-469-4698 | |
Trinity Health And Wellness Center, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 576 N Sunrise Ave, Suite 220, Roseville, CA 95661 Phone: 916-773-3444 Fax: 916-773-3474 | |
Manish Upadhyay, Md, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 508 Gibson Dr, Suite No 270, Roseville, CA 95678 Phone: 916-786-6727 Fax: 916-786-6748 | |
Uc Davis Medical Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1620 E Roseville Pkwy Ste 200, Roseville, CA 95661 Phone: 916-783-7109 |